✦ LIBER ✦

BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF V600E mutation

✍ Scribed by Young, Kate; Minchom, Anna; Larkin, James

Book ID: 120278976
Publisher: Future Medicine
Year: 2012
Tongue: English
Weight: 702 KB
Volume: 8
Category: Article
ISSN: 1479-6694
DOI: 10.2217/fon.12.43

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved Survival with Vemurafenib in Me

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

✍ Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, 📂 Article 📅 2011 🏛 Massachusetts Medical Society 🌐 English ⚖ 609 KB

Overwhelming response to Dabrafenib in a

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma

✍ Giovanni Ponti, Aldo Tomasi, Giovanni Pellacani 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 196 KB

Biomarker analysis of on-treatment and a

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma

✍ Yan, Yibing; McArthur, Grant; Hamid, Omid; Puzanov, Igor; Gonzalez, Rene; Gajews 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 88 KB

1403 POSTER DISCUSSION Molecular Testing

1403 POSTER DISCUSSION Molecular Testing for BRAF V600 Mutations in Clinical Trials of the BRAF Inhibitor Vemurafenib (RG7204/PLX4032) in Metastatic Melanoma – a Comparison With Sánger Sequencing

✍ S. Anderson; K. Bloom; R. Schilling; J.R.J. Lee; R. Langland; H. Halait; H.J. La 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Phase 1/2 study of subcutaneous and intr

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

✍ Wim H.J. Kruit; Heidi H. van Ojik; Vincent G. Brichard; Bernard Escudier; Thierr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 845 KB

The purpose of this phase 1/2 study was to evaluate toxicity, tumor evolution and immunologic response following administration of a fixed dose of a recombinant MAGE-3 protein by subcutaneous and intradermal routes in the absence of immunologic adjuvant. Thirty-two patients with detectable metastati